Amarin Corporation (AMRN) Stock: Worth Considering Regardless Of Rumors

Amarin Corporation AMRN Stock News

Amarin Corporation plc (NASDAQ: AMRN) is seeing quite a bit of after-hours chatter this evening. According to various posts on message boards and social media, the company’s scripts may be better than expected due to a rumor surrounding Symphony Health.

Whether or not the rumor is true, I believe that there’s quite a bit of value locked into AMRN, and now may be a great time to get in. Here’s what’s happening:

AMRN Finds Itself In The Center Of A Rumor

As mentioned above, There’s a rumor surfacing in the after-hours this evening about Amarin Corporation. According to the rumor, Syphony Health is having trouble getting its hands on data with regard to prescription sales.

If the rumor is true, the prescriptions in the fourth quarter may be better than reported. Let’s not forget, the fourth quarter was the best quarter for Vascepa sales to date, with about $77 million in net revenue reported as a result of sales of the drug.

A good example of how the rumor is being circulated is a post from BBecker3138 on StockTwits. In this post, BBecker3138 said:

$AMRN The rumor is Symphony is having trouble getting data. If true, scripts r even better than being reported.

Although that would be great news for AMRN and its investors, I generally don’t make moves based on rumors. After all, rumors are one of the most common ways that the market is manipulated. Nonetheless, even without this rumor, there are plenty of reasons to be excited about the stock.

Take A Look At Vascepa Sales

Brad Loncar of has done a great job of tracking Vascepa sales. He has even put together a chart that gives a great visual of what we’re seeing. See his chart below:
Amarin (AMRN) Stock: Vascepa Sales Chart

As you can see from the chart above, Vascepa sales may stumble here and there, but all in all, the trend in sales in an upward one. Moreover, in the fourth quarter of 2018, with $77 million in net product revenue, the company achieved record sales.

Coming Catalysts 

If increasing Vascepa sales isn’t enough to gain some interest in AMRN, there are two big coming catalysts that will likely do just that. These include:

Coming sNDA Submission For Vascepa 

Currently Vascepa is approved by the FDA to reduce triglycerides (fats) levels in adults. However, Amarin may soon benefit from an expanded label, leading to a potentially robust increase in sales. 

In a report recently released by AMRN that discussed 2018 preliminary results and 2019 outlook, the company said that it plans on submitting a sNDA to the FDA by the end of the first quarter of 2019. 

The label expansion goals come after a massive study of 8,179 statin-treated adults, known as the REDUCE-IT study. 59% of patients involved in the study had diabetes at baseline. Moreover, 71% of patients had established cardiovascular disease at the time of enrollment. 

The data from REDUCE-IT showed a 31% risk reduction for heart attack, a 28% risk reduction for stroke, and a 20% reduction of risk for cardiovascular-related death. Due to these results, the company seeks to expand the label to include an indication to treat the residual cardiovascular risk of patients with high triglyceride levels. 

Should the label expansion be approved, Vascepa will be the first drug on the market that has been approved for this indication. Nonetheless, between now and then, there are plenty of catalysts ahead. Including:

  • sNDA submission;
  • potential updates throughout the FDA review process; and
  • the potential approval of the Vascepa label expansion. 

Potential Vascepa Approval In Canada

Another list of potential coming catalysts has to do with the company’s efforts to get Vascepa approved in Canada. In fact, on April 1, 2019, AMRN announced that Health Canada granted priority review status for its New Drug Submission surrounding Vascepa capsules. 

As a result of the Priority Review status, Amarin Corporation will enjoy a shorter review period. Generally, the review period for new drugs in Canada is 355 days. However, under Priority Review, AMRN can expect to receive an answer from Health Canada within 215 days of the New Drug Submission. 

Of course, this comes with several potential catalysts as well. Some of them include:

  • NDS submission in Canada (expected by the end of April, 2019);
  • updates with regard to the regulatory process in Canada;
  • the potential, and highly likely approval of Vascepa in Canada. 

AMRN Is A Potential Takeover Target

Finally, it’s worth mentioning that at the moment, Amarin makes a great potential takeover target. The reason for this is simple. Vascepa is already approved in the United States. However, without the label expansion and Canadian approval under its belt, larger companies are still capable of getting a discount on the company if they choose to acquire it soon. 

The value that AMRN would offer to a larger company is incredible. Think about the sales growth that would likely happen if the label expansion for Vascepa happened. With Aspirin no longer being recommended by the American Heart Association unless prescribed by your doctor, the market is looking for a replacement for daily, preventative measures in heart health. Vascepa, could fill that void if the label expansion is approved, opening the door to incredible growth in revenue. 

Moreover, with AMRN knocking on the door to potential Vascepa approval in Canada, the argument that the stock is highly undervalued at the moment only grows stronger. With that said, a big player has a lot to gain if they act quickly here. 

Final Thoughts

At the end of the day, when digging into Amarin Corporation, it is hard to argue against the idea that the stock represents a potentially lucrative opportunity. With increasing Vascepa sales and coming catalysts that will likely put rocket boosters under sale numbers, this is a stock that is worth digging into!

What Do You Think?

Where do you think AMRN is headed moving forward? Join the discussion in the comments below!

6 thoughts on “Amarin Corporation (AMRN) Stock: Worth Considering Regardless Of Rumors”

  1. James W. Novak DDS

    Hi JR, my name is James W. Novak DDS, a recently retired Doctor of Dental Surgery. Had a heart attack with bypass surgery, in 2001. At first I watched what I ate,etc. I had quit smoking a year before HA. I’ve dealt with high risk pharmaceuticals in the past, but when I was initially prescribed Vascepa, I didn’t realize I had purchased stock in Amarin. Started taking Vascepa, didn’t watch what I ate or exercise, but saw an improvement in my lipid scores within a few months. In May 2015: Non HdLCholesterol = 181 mg/dL,Triglycerides 282 mg/dL, Cholesterol 206 mg/dL,LDL Cholesterol = 125 mg/dL. Improvement in scores as time went on. September 2018 Lipid scores: Triglycerides 94,Cholesterol 130 mg/dL, LDL Cholesterol = 79, Non LDL Cholesterol = 98 mg/dL. In closing, am anxious to have my lipid scores on 4/9/19, see what scores I will have with eating properly, Medit. Diet and a little exercise. I also stopped taking my 81 mg Aspirin in Sept. 2018 because my left nostril would bleed occasionally. Once I stopped taking the aspirin, no more bleeding. I suspect that Vascepa may act as an anticoagulant. I’m a believer!

    1. Hey Dr. Novak,

      Thank you for sharing your story. After digging into Vascepa trial data, I’m with you. I believe that the drug has incredible potential to reduce cardiac risk, improve Cholesterol and Triglyceride levels, and more. A great investment in my opinion. Thanks again for weighing in!

  2. Great article about Amarin’s Vascepa. I love that chart. After taking Vascepa, I haven’t had a recurrence of a very uncomfortable, and I was told incurable, condition called Brachial Radial Pruritis. It’s a condition where the forearms itch intensely. I use to scratch my forearms raw. Nothing helped. I haven’t had an episode of itching in over a year. There are many other benefits to taking high dose purified prescription EPA (Vascepa) besides the incredible cardio protective benefits proved in the 7 year CVOT trial ReduceIt. I take it because of long standing CVD and family history of strokes and MI’s. I feel great, I’m leaner than I’ve been in 15 years, and all my labs and cardiovascular test are great. As a side , I didn’t qualify for the current FDA indication but my Cardiologist felt I should be on it and wrote me an off label script. At first I had to fight for insurance coverage but now it’s good.i highly recommend talking to your doctor if you have CVD and or Diabetes. It’s amazing.

    1. Hey Jeff,

      Thanks for sharing your story. It proves to further validate the impressive work that AMRN is doing with Vascepa and the change in quality of life for the patients that can benefit from the treatment!

  3. I used to get migraines weekly. Haven’t had a single migraine in over a year since starting with Vascepa. I haven’t changed my activities or diet so can only assume Vascepa is the reason I’m not getting them any longer. Also, I used to have high trigs (300’s) and a serious family history of diabetes and heart disease, now my trigs are 80s-90s. Blood pressure also used to be 140/90, now consistently 105/70. Vascepa is the closest thing to a miracle drug as I’ve ever seen. No migraines have been a very welcome side effect 🙂

    1. Hey Joe,

      Thanks for sharing your story. I’m happy to hear that you’re no longer having migraines and that your stats are heading back to where they should be!!!

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.